BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Aug 22, 2005
 |  BioCentury  |  Emerging Company Profile

Cerenis: Synthesize, don't mimic

Drugs such as statins can reduce circulating cholesterol and prevent the progression of atherosclerotic plaques, but none are able to promote the regression of plaques. Cerenis Therapeutics Holding SA says that it can address this limitation, first through administration of synthetic high density lipoprotein (HDL) - the "good" cholesterol - and later through the use of small molecule therapeutics.

Cerenis (Toulouse, France) this week was expected to announce a series A financing of E25 million ($31.1 million). Investors will include Sofinnova; Healthcap; Alta Partners; EDF; and Japanese venture capital firm NIF.

Even though it has been known for some time that HDL cholesterol can reduce atherosclerotic plaques, the question has been how to raise HDL levels or increase HDL function. A number of stra-tegies are being tried, but Cerenis is going to be the...

Read the full 652 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >